JP2022065035A5 - - Google Patents

Download PDF

Info

Publication number
JP2022065035A5
JP2022065035A5 JP2022017827A JP2022017827A JP2022065035A5 JP 2022065035 A5 JP2022065035 A5 JP 2022065035A5 JP 2022017827 A JP2022017827 A JP 2022017827A JP 2022017827 A JP2022017827 A JP 2022017827A JP 2022065035 A5 JP2022065035 A5 JP 2022065035A5
Authority
JP
Japan
Prior art keywords
compound according
item
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022017827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022065035A (ja
JP7515526B2 (ja
Filing date
Publication date
Priority claimed from JP2018568186A external-priority patent/JP7023876B2/ja
Application filed filed Critical
Publication of JP2022065035A publication Critical patent/JP2022065035A/ja
Publication of JP2022065035A5 publication Critical patent/JP2022065035A5/ja
Application granted granted Critical
Publication of JP7515526B2 publication Critical patent/JP7515526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022017827A 2016-03-18 2022-02-08 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置 Active JP7515526B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662310409P 2016-03-18 2016-03-18
US62/310,409 2016-03-18
JP2018568186A JP7023876B2 (ja) 2016-03-18 2017-03-20 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
PCT/US2017/023206 WO2017161370A1 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018568186A Division JP7023876B2 (ja) 2016-03-18 2017-03-20 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Publications (3)

Publication Number Publication Date
JP2022065035A JP2022065035A (ja) 2022-04-26
JP2022065035A5 true JP2022065035A5 (enExample) 2022-05-19
JP7515526B2 JP7515526B2 (ja) 2024-07-12

Family

ID=59851645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018568186A Active JP7023876B2 (ja) 2016-03-18 2017-03-20 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
JP2022017827A Active JP7515526B2 (ja) 2016-03-18 2022-02-08 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018568186A Active JP7023876B2 (ja) 2016-03-18 2017-03-20 α5含有GABAA受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Country Status (17)

Country Link
US (4) US10906909B2 (enExample)
EP (2) EP4129297A1 (enExample)
JP (2) JP7023876B2 (enExample)
AU (2) AU2017235665B2 (enExample)
CA (1) CA3016491A1 (enExample)
CY (1) CY1125576T1 (enExample)
DK (1) DK3439665T3 (enExample)
ES (1) ES2926918T3 (enExample)
HR (1) HRP20221098T1 (enExample)
HU (1) HUE059774T2 (enExample)
LT (1) LT3439665T (enExample)
PL (1) PL3439665T3 (enExample)
PT (1) PT3439665T (enExample)
RS (1) RS63674B1 (enExample)
SI (1) SI3439665T1 (enExample)
SM (1) SMT202200372T1 (enExample)
WO (1) WO2017161370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US12636291B2 (en) * 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
JP2024533306A (ja) * 2021-09-08 2024-09-12 ユーダブリューエム・リサーチ・ファウンデーション,インコーポレーテッド 認知および気分症状の処置のためのイミダゾベンゾジアゼピン
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023059443A1 (en) * 2021-10-07 2023-04-13 Pantherics Incorporated Methods and compounds for treating inflammation
US20260125388A1 (en) * 2022-10-04 2026-05-07 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
IT202400001089A1 (it) * 2024-01-22 2025-07-22 Fondazione St Italiano Tecnologia Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4226768A (en) 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20030176456A1 (en) 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
USRE47475E1 (en) 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
AU2005260650A1 (en) 2004-06-30 2006-01-12 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US7595395B2 (en) * 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US20100130479A1 (en) 2005-05-16 2010-05-27 Cook James M Gabaergic Agents to Treat Memory Deficits
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
DE102006023554A1 (de) 2006-05-19 2007-11-22 Zf Friedrichshafen Ag Ermittlung der Drehzahl einer Getriebewelle
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US8923318B2 (en) 2008-10-02 2014-12-30 Telefonaktiebolaget L M Ericsson (Publ) Wireless communication system and method for assigning a channel in said wireless communication system
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses

Similar Documents

Publication Publication Date Title
DE844741C (de) Verfahren zur Herstellung von heterocyclischen Carbaminsaeureestern
JP2022550640A5 (enExample)
KR101086678B1 (ko) 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
JP2022533912A5 (enExample)
JP2018531981A5 (enExample)
RU2003128535A (ru) Гетерополициклическое соединение (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, ассоциированного с активацией метаботропных глютаматных рецепторов (варианты)
JPH11246411A (ja) コルチコトロピン放出因子アンタゴニスト製造用中間体
JPH0572384B2 (enExample)
CH631703A5 (de) Verfahren zur herstellung von pyrrolidinverbindungen.
DE69021823T2 (de) 3-Aryl-Oxazolidinone, Verfahren zu ihrer Herstellung und ihre Anwendung in der Therapie.
DD267727A5 (de) Verfahren zur herstellung von arylcyclobutylalkylamin-derivaten
DE4211812A1 (de) Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
DE1216878B (de) Verfahren zur Herstellung von coronargefaesserweiternden Derivaten des 7-Hydroxy-2-oxo-1, 2-dihydrochinolins
DE3041155A1 (de) Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
JP2025502615A5 (enExample)
RU2019128576A (ru) Сокристаллы замещенных глициновых соединений и их применение
JP2022526015A5 (enExample)
JP2021534221A5 (enExample)
AT391866B (de) Verfahren zur herstellung neuer s-triazolo (1,5-a) pyrimidine
RU2006103790A (ru) Производные такрина в качестве ингибиторов ацетилхолинэстеразы
DE69615396T2 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
FR2466462A2 (fr) Derives d'alkylenediamines, leur preparation et leur application en therapeutique
JPS59227884A (ja) 新規な7−ヒドロキシアルキルカンプトテシン誘導体
DE3111025A1 (de) "aminosaeurederivate, deren herstellung und deren verwendung als arzneimittel"
DE962077C (de) Verfahren zur Herstellung von neuen Tetrakis-(triorganosilyl)-titanen